Pharmacology, Toxicology and Pharmaceutical Science
Solid Malignant Neoplasm
99%
Malignant Neoplasm
70%
Neoplasm
68%
Pharmacodynamics
60%
Monotherapy
54%
Pharmacokinetics
50%
Bladder Cancer
48%
Castration Resistant Prostate Cancer
48%
Diseases
42%
Pembrolizumab
40%
Antitumor Activity
39%
Biological Marker
39%
Cemiplimab
32%
Transforming Growth Factor Beta
32%
Phosphotransferase Inhibitor
32%
Seprase
32%
Docetaxel
29%
Maximum Tolerated Dose
28%
Clinical Trial
26%
CD8 Antigen
23%
Immunotherapy
22%
Disease Exacerbation
21%
Immunocytokine
21%
Nivolumab
19%
Immune Checkpoint Inhibitor
18%
Diarrhea
17%
Sodium Fluoride
16%
Chemoradiation Therapy
16%
Olaparib
16%
Cabazitaxel
16%
Aurora A Kinase
16%
Aneuploidy
16%
Clinical Research
16%
Rolipram
16%
Clinical Study
16%
Interleukin 1 Receptor Accessory Protein
16%
Ipilimumab
16%
Acetonitrile
16%
Protein Antibody
16%
Structure Activity Relationship
16%
Formate
16%
Ritonavir
16%
Cetuximab
16%
Head and Neck Squamous Cell Carcinoma
16%
Observational Study
16%
Long Term Survival
16%
Lutetium 177
16%
Overall Survival
14%
Chemotherapy
14%
Adverse Event
13%
Medicine and Dentistry
Urothelial Cancer
100%
Neoplasm
44%
Diseases
38%
Biological Marker
37%
Cancer of Unknown Primary Origin
32%
Castration Resistant Prostate Cancer
32%
Prostate Cancer
32%
Pembrolizumab
31%
Clinical Trial
29%
Overall Survival
28%
Bladder
27%
Whole Genome Sequencing
25%
Cystectomy
25%
Disease Exacerbation
24%
Progression Free Survival
22%
Immunotherapy
21%
Screening Test
20%
Malignant Neoplasm
20%
Cancer
20%
Immune Checkpoint Inhibitor
20%
Monotherapy
20%
Bladder Cancer
19%
Muscle Invasive Bladder Cancer
19%
Cancer Registry
19%
Long Term Survival
18%
Decision Making
18%
Positron Emission Tomography-Computed Tomography
17%
Metastatic Bladder Cancer
16%
Nivolumab
16%
Aneuploidy
16%
Chemoimmunotherapy
16%
Lymph Node Metastasis
16%
Experimental Therapy
16%
Neoadjuvant Chemotherapy
16%
Olaparib
16%
Chemoradiotherapy
16%
Conservative Treatment
16%
Clinical Research
16%
Treatment Duration
16%
BRCA1
16%
T-Helper Cell
16%
Cell-Free DNA
16%
Ipilimumab
16%
Cytotoxic T-Cell
16%
Cabazitaxel
16%
Post-Hoc Analysis
16%
Comprehensive Genomic Profiling
16%
Observational Study
16%
Urologist
16%
Nurse Practitioner
16%
Immunology and Microbiology
Overall Survival
37%
Macrophage
32%
Pembrolizumab
27%
Pharmacodynamics
24%
T Cell
23%
Cytotoxic T-Cell
21%
Progression Free Survival
20%
Immunotherapy
18%
down Regulation
18%
Cemiplimab
16%
Interferon Type I
16%
T-Helper Cell
16%
Neutrophil
16%
Lymph Node
16%
Macrophage Activation
16%
Lymphocyte Activation
16%
Transforming Growth Factor Beta
16%
Muscle
16%
Avelumab
16%
Whole Genome Sequencing
16%
Immunocompetent Cell
9%
T Cell Receptor
8%
Arm
8%
Antigen Presentation
8%
Cancer Staging
8%
Transcriptomics
8%
Hepatobiliary System
8%
Tumor Immunity
8%
Blood Plasma
7%
Prevalence
7%
Cell Population
6%
Myeloid
6%
Lymphocyte
6%
RNA Sequencing
5%
